Comparative Pharmacology
Head-to-head clinical analysis: CINOXACIN versus FLOXIN IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CINOXACIN versus FLOXIN IN DEXTROSE 5 IN PLASTIC CONTAINER.
CINOXACIN vs FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial DNA gyrase (topoisomerase II), blocking DNA replication and transcription.
Of course, I can help you with that. However, I must clarify that there is no drug called "FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER". "Floxin" is a brand name for ofloxacin, an antibiotic. Ofloxacin is a fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV, thereby inhibiting DNA replication and transcription.
1 g orally twice daily for 7-14 days.
400 mg (as ofloxacin) intravenously every 12 hours for 7-14 days.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5 hours in healthy adults. Prolonged in renal impairment (up to 20-30 hours in anuria).
Clinical Note
moderateCinoxacin + Digoxin
"Cinoxacin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCinoxacin + Digitoxin
"Cinoxacin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCinoxacin + Deslanoside
"Cinoxacin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateCinoxacin + Acetyldigitoxin
"Cinoxacin may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is 6-8 hours in patients with normal renal function; prolonged in renal impairment (up to 30 hours in severe cases).
Primarily renal excretion as unchanged drug (approximately 60-70%) and as glucuronide conjugates (approximately 20-30%). Biliary/fecal excretion accounts for less than 5%.
Primarily renal (80-90% unchanged); biliary/fecal <4%.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic